NCT02285374 - Efavirenz to Dolutegravir Switch in Patients With CNS Toxicity | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

December 31, 2015

Conditions

HIV

Interventions

DRUG

Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir

Arm 1: Switch efavirenz to dolutegravir immediately (at baseline) for 12 weeks Arm 2: Continue on pre-study regimen (unchanged) for 4 weeks and then switch efavirenz to dolutegravir for 12 weeks

Trial Locations (1)

SW10 9TH

Chelsea and Westminster Hospital, London